These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 32988414)

  • 1. Pembrolizumab- and ipilimumab-induced diabetic ketoacidosis and isolated adrenocorticotropic hormone deficiency: a case report.
    Porntharukchareon T; Tontivuthikul B; Sintawichai N; Srichomkwun P
    J Med Case Rep; 2020 Sep; 14(1):171. PubMed ID: 32988414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pituitary immune-related adverse events induced by programmed cell death protein 1 inhibitors in advanced lung cancer patients: A report of 3 cases].
    Gu YC; Liu Y; Xie C; Cao BS
    Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 54(2):369-375. PubMed ID: 35435206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isolated adrenocorticotropic hormone deficiency associated with sintilimab therapy in a patient with advanced lung adenocarcinoma: a case report and literature review.
    Lin SH; Zhang A; Li LZ; Zhao LC; Wu LX; Fang CT
    BMC Endocr Disord; 2022 Sep; 22(1):239. PubMed ID: 36153581
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fulminant ACTH decrease following diabetic ketoacidosis induced by immune checkpoint inhibitor combination therapy with nivolumab and ipilimumab: A case report.
    Iesaka H; Kameda H; Miya A; Nomoto H; Cho KY; Nakamura A; Abe T; Shinohara N; Atsumi T
    Medicine (Baltimore); 2023 Dec; 102(51):e36664. PubMed ID: 38134115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isolated adrenocorticotropic hormone deficiency and thyroiditis associated with nivolumab therapy in a patient with advanced lung adenocarcinoma: a case report and review of the literature.
    Ohara N; Kobayashi M; Ohashi K; Ito R; Ikeda Y; Kawaguchi G; Yoneoka Y; Hasegawa G; Takada T
    J Med Case Rep; 2019 Mar; 13(1):88. PubMed ID: 30909965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recovery from secondary adrenal insufficiency in a patient with immune checkpoint inhibitor therapy induced hypophysitis.
    Thapi S; Leiter A; Galsky M; Gallagher EJ
    J Immunother Cancer; 2019 Sep; 7(1):248. PubMed ID: 31511065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined checkpoint inhibitor therapy causing diabetic ketoacidosis in metastatic melanoma.
    Changizzadeh PN; Mukkamalla SKR; Armenio VA
    J Immunother Cancer; 2017 Dec; 5(1):97. PubMed ID: 29254501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isolated ACTH deficiency during single-agent pembrolizumab for squamous cell lung carcinoma: a case report.
    Tanaka S; Kushimoto M; Nishizawa T; Takubo M; Mitsuke K; Ikeda J; Fujishiro M; Ogawa K; Tsujino I; Suzuki Y; Abe M
    Clin Diabetes Endocrinol; 2020; 6():1. PubMed ID: 31921440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rare, late onset of immune checkpoint inhibitor-induced type 1 diabetes mellitus in a patient with small-cell lung cancer treated with serplulimab: a case report and review of the literature.
    Ning P; Liu S; Cao H
    J Med Case Rep; 2024 Jan; 18(1):51. PubMed ID: 38247005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diabetic Ketoacidosis as a Delayed Immune-Related Event after Discontinuation of Nivolumab.
    Mae S; Kuriyama A; Tachibana H
    J Emerg Med; 2021 Mar; 60(3):342-344. PubMed ID: 33097350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pembrolizumab-induced type 1 diabetes.
    Maia A; Soares DM; Azevedo S; Pereira T; Amaral C
    J Oncol Pharm Pract; 2024 Sep; 30(6):1118-1121. PubMed ID: 38766907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical course and management of pembrolizumab-associated isolated adrenocorticotrophic hormone deficiency: a new case and literature review.
    Oğuz SH; Ünlütürk U; Aksoy S; Erbas T
    Immunotherapy; 2021 Oct; 13(14):1157-1163. PubMed ID: 34387129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Late-onset isolated adrenocorticotropic hormone deficiency caused by nivolumab: a case report.
    Takeno A; Yamamoto M; Morita M; Tanaka S; Kanazawa I; Yamauchi M; Kaneko S; Sugimoto T
    BMC Endocr Disord; 2019 Feb; 19(1):25. PubMed ID: 30782163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isolated Adrenocorticotropic Hormone Deficiency Associated with Severe Hyperkalemia During Pembrolizumab Therapy in a Patient with Ureteral Cancer and an Ileal Conduit: A Case Report and Literature Review.
    Hinata Y; Ohara N; Sakurai Y; Koda R; Yoneoka Y; Takada T; Hara N; Nishiyama T
    Am J Case Rep; 2021 Jul; 22():e931639. PubMed ID: 34262010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Severe Case of Diabetic Ketoacidosis and New-Onset Type 1 Diabetes Mellitus Associated with Anti-Glutamic Acid Decarboxylase Antibodies Following Immunotherapy with Pembrolizumab.
    Kedzior SK; Jacknin G; Hudler A; Mueller SW; Kiser TH
    Am J Case Rep; 2021 Jun; 22():e931702. PubMed ID: 34185763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer.
    Godwin JL; Jaggi S; Sirisena I; Sharda P; Rao AD; Mehra R; Veloski C
    J Immunother Cancer; 2017; 5():40. PubMed ID: 28515940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune checkpoint inhibitor-induced isolated adrenocorticotropic hormone deficiency: a systematic review.
    Wang F; Shi X; Yu X; Yang Y
    Front Endocrinol (Lausanne); 2024; 15():1326684. PubMed ID: 38318292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. When Hormones are Being Difficult: A Rare Case and the Literature Review of Pembrolizumab-Induced Polyendocrinopathy.
    Tayyeb M; Tariq M; Khan AM; Khalid F; Meghal T; Du D
    J Community Hosp Intern Med Perspect; 2023; 13(6):90-94. PubMed ID: 38596553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A case of pembrolizumab-induced severe DKA and hypothyroidism in a patient with metastatic melanoma.
    Hakami OA; Ioana J; Ahmad S; Tun TK; Sreenan S; McDermott JH
    Endocrinol Diabetes Metab Case Rep; 2019 Mar; 2019():. PubMed ID: 30836329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of hypophysitis in a cohort of patients with metastatic melanoma and prostate cancer treated with ipilimumab.
    Brilli L; Danielli R; Ciuoli C; Calabrò L; Di Giacomo AM; Cerase A; Paffetti P; Sestini F; Porcelli B; Maio M; Pacini F
    Endocrine; 2017 Dec; 58(3):535-541. PubMed ID: 28401443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.